PEDEvidence
Latest studiesAll research questions
RESEARCH BY QUESTION

What changes with testosterone treatment?

Muscle, hormone exposure, energy, sexual function and health tradeoffs.

The selected trials answer different questions in different populations. Changes in muscle, fatigue, sexual function and safety outcomes should be read separately.

Bhasin et al., testosterone dose-response trial Snyder et al., Testosterone Trials Resnick et al., cognitive function trial
Compare measured outcomesWatch relevant trialsOpen focused testosterone research
Human

How did dose and achieved levels relate to muscle outcomes?

20 weeks; weekly enanthate with a GnRH agonist. These are experimental regimens.

Demonstrated findings

Across graded testosterone exposures, fat-free mass, muscle size and strength increased with dose. Mood and sexual function did not significantly change at any dose.

Selected groups from this experiment
Studied doseMean trough total TFat-free mass change
125 mg/week542 ng/dL+3.4 kg
300 mg/week1,345 ng/dL+5.2 kg
600 mg/week2,370 ng/dL+7.9 kg

Group averages at the studied regimens, not a dosing recommendation or prediction of personal gains.

Limitations & adverse findings

Hemoglobin increased and HDL cholesterol decreased with higher concentrations. Fat-free mass includes more than muscle.

What might this mean? · interpretation

Different outcomes can respond differently to increasing hormone exposure.

What might this mean, and what would change the interpretation?

61 healthy men aged 18–35; endogenous production was suppressed. Short-term group averages cannot predict an individual response.

What would clarify this: Longer trials measuring function and adverse outcomes across comparable exposures.

Findings reviewed · abstract

Checked Sep 15, 2026 against the linked abstract. This reading note is not a formal risk-of-bias appraisal.

Bhasin et al., testosterone dose-response trial
Human · TestosteroneDo libido, mood and energy improve together?
Human

Do libido, mood and energy improve together?

Testosterone gel versus placebo for 1 year, titrated toward young-adult normal levels.

Demonstrated findings

Sexual activity, desire and erectile function improved. Mood improved slightly, but the primary fatigue measure showed no significant benefit.

Limitations & adverse findings

The study was too small to settle uncommon safety outcomes.

What might this mean? · interpretation

An effect on sexual function does not establish an equivalent effect on energy or motivation.

What might this mean, and what would change the interpretation?

790 symptomatic men aged 65 or older with low testosterone. Results do not predict responses in younger men or at higher exposures.

What would clarify this: Trials in younger symptomatic populations with prespecified energy and motivation measures.

Findings reviewed · abstract

Checked Sep 15, 2026 against the linked abstract. This reading note is not a formal risk-of-bias appraisal.

Snyder et al., Testosterone Trials
Human · TestosteroneDoes testosterone treatment improve memory?
Human

Does testosterone treatment improve memory?

Daily gel versus placebo for 1 year; men aged 65 or older.

Demonstrated findings

In the 493-person memory-impaired subgroup, testosterone did not significantly improve verbal memory, visual memory, executive function or spatial ability versus placebo.

Limitations & adverse findings

This report shares the Testosterone Trials registration with other reports; it is not an independent trial population.

What might this mean? · interpretation

Improved hormone levels did not translate into cognitive gains on these tests.

What might this mean, and what would change the interpretation?

Older men with low testosterone and age-associated memory impairment; this does not resolve every cognitive question in younger adults.

What would clarify this: Replication in different populations using prespecified cognitive and daily-function outcomes.

Findings reviewed · abstract

Checked Sep 15, 2026 against the linked abstract. This reading note is not a formal risk-of-bias appraisal.

Resnick et al., cognitive function trial
Human · TestosteroneHow did testosterone and estradiol contribute differently?
Human

How did testosterone and estradiol contribute differently?

400 men across two cohorts; 16 weeks; gel and controlled suppression.

Demonstrated findings

Under experimental hormone suppression, androgen deficiency accounted for loss of lean mass, muscle size and strength. Estrogen deficiency mainly accounted for increased body fat; both contributed to reduced sexual function.

What might this mean? · interpretation

Reducing estrogen is not automatically aligned with improving every body-composition or sexual outcome.

What might this mean, and what would change the interpretation?

Healthy men received hormone suppression and graded gel doses, with or without anastrozole. This does not define an optimal estradiol target during routine treatment.

What would clarify this: Trials testing specific clinical questions about estradiol management.

Findings reviewed · abstract

Checked Sep 15, 2026 against the linked abstract. This reading note is not a formal risk-of-bias appraisal.

Finkelstein et al., gonadal steroids trial
Human · TestosteroneWas conversion to DHT necessary for the muscle response?
Human

Was conversion to DHT necessary for the muscle response?

Healthy men aged 18–50; 20 weeks of graded testosterone enanthate with dutasteride or placebo.

Demonstrated findings

Fat-free mass and strength responses to graded testosterone did not differ significantly when DHT production was suppressed with dutasteride.

Limitations & adverse findings

A nonsignificant difference is not proof that DHT has no physiological role or that blocking it has no tradeoffs.

What might this mean? · interpretation

Conversion to DHT was not required for the measured anabolic response in this experiment.

What might this mean, and what would change the interpretation?

139 men were randomized and 102 completed. This suppression study does not test whether adding DHT improves cognition, motivation or muscle growth.

What would clarify this: Direct trials of the specific DHT-related outcome and exposure being proposed.

Findings reviewed · abstract

Checked Sep 15, 2026 against the linked abstract. This reading note is not a formal risk-of-bias appraisal.

Bhasin et al., 5α-reductase trial
Human · TestosteroneWhat did TRAVERSE establish about cardiovascular events?
Human

What did TRAVERSE establish about cardiovascular events?

1.62% gel targeting 350–750 ng/dL; mean treatment 21.7 months, follow-up 33 months.

Demonstrated findings

The primary cardiovascular event occurred in 7.0% with testosterone and 7.3% with placebo. The trial met its prespecified noninferiority criterion.

Limitations & adverse findings

Atrial fibrillation, acute kidney injury and pulmonary embolism occurred more often in the testosterone group.

What might this mean? · interpretation

This supports a bounded conclusion about major cardiovascular events in the studied replacement setting.

What might this mean, and what would change the interpretation?

5,246 men aged 45–80 with low testosterone and existing or increased cardiovascular risk. Results do not establish safety at higher exposures or across all formulations.

What would clarify this: Longer follow-up and studies of different exposures and delivery methods.

Findings reviewed · abstract

Checked Sep 15, 2026 against the linked abstract. This reading note is not a formal risk-of-bias appraisal.

Lincoff et al., TRAVERSE
Human · TestosteroneWhat does the prostate analysis leave unresolved?
Human

What does the prostate analysis leave unresolved?

Topical gel versus placebo; 5,204 men analyzed.

Demonstrated findings

High-grade prostate cancer occurred in 5 of 2,596 testosterone-treated men and 3 of 2,602 placebo-treated men. The difference was not statistically significant; PSA rose more with testosterone.

Limitations & adverse findings

This is a TRAVERSE analysis, sharing its registration with the cardiovascular report.

What might this mean? · interpretation

Low event counts in screened men support a limited conclusion, not proof of no long-term prostate risk.

What might this mean, and what would change the interpretation?

Participants at high prostate-cancer risk were excluded. Few events and limited follow-up constrain precision.

What would clarify this: Longer follow-up and evidence in populations excluded from this trial.

Findings reviewed · abstract

Checked Sep 15, 2026 against the linked abstract. This reading note is not a formal risk-of-bias appraisal.

Bhasin et al., TRAVERSE prostate analysis

What would move this question forward?

How do baseline deficiency, achieved levels and delivery method change the balance of measured outcomes?

  • Baseline and achieved testosterone levels
  • Formulation and studied exposure
  • Muscle size and function alongside lean mass
  • Symptom instruments and adverse outcomes

For emerging mechanisms, replication and the absence of the predicted effect both matter. Human implications remain hypotheses until the relevant outcomes are tested.

Community experiences & questions

A sourced community summary has not been prepared for this question yet. The compound pages link to public discussions for further exploration.

Self-selected accounts can reveal questions and experiences; they do not establish a response rate or verified product identity.

Keep exploring

What has been studied for preserving muscle during weight loss?Does more lean mass mean more strength?